Index - P/E - EPS (ttm) - Insider Own 74.74% Shs Outstand 19.51M Perf Week 1.40%
Market Cap 212.66M Forward P/E - EPS next Y - Insider Trans 80.03% Shs Float 4.93M Perf Month -
Income - PEG - EPS next Q - Inst Own - Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh - P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh - P/C - EPS next 5Y - ROE - 52W Range 9.40 - 12.30 Perf YTD 1.68%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -11.38% Beta -
Dividend TTM - Quick Ratio - Sales past 5Y 0.00% Gross Margin - 52W Low 16.02% ATR (14) 1.53
Dividend Ex-Date - Current Ratio - EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 12.11% -
Employees 58 Debt/Eq - Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq - EPS Q/Q - Payout - Rel Volume 0.43 Prev Close 10.90
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 223.03K Price 10.90
SMA20 1.63% SMA50 1.63% SMA200 1.63% Trades
Volume 103,895 Change 0.00%
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Northpond Ventures II GP, LLC 10% Owner Oct 15 '24 Buy 11.00 763,636 8,399,996 763,636 Oct 17 06:34 PM AH Equity Partners Bio I, L.L. 10% Owner Oct 15 '24 Buy 11.00 727,272 7,999,992 1,579,885 Oct 17 05:05 PM Enavate Sciences GP, LLC 10% Owner Oct 15 '24 Buy 11.00 1,363,636 14,999,996 3,785,802 Oct 17 04:15 PM Polaris Management Co. VII, L. 10% Owner Oct 15 '24 Buy 11.00 909,090 9,999,990 909,090 Oct 15 06:00 PM 5AM Partners VI, LLC 10% Owner Oct 15 '24 Buy 11.00 909,090 9,999,990 2,625,145 Oct 15 05:56 PM Nashat Amir Director Oct 15 '24 Buy 11.00 909,090 9,999,990 909,090 Oct 15 05:49 PM Schwab Andrew J. Director Oct 15 '24 Buy 11.00 909,090 9,999,990 2,625,145 Oct 15 05:48 PM Cohenour Jason Director Jun 05 '24 Sale 0.83 8,640 7,176 0 Jun 06 09:00 AM Cohenour Jason Director Mar 05 '24 Option Exercise 0.00 7,824 0 10,962 Mar 07 07:41 PM Scott Richard M. Chief Legal Officer, Secretary Nov 05 '23 Option Exercise 0.00 3,167 0 53,090 Nov 07 02:48 PM
Index RUT P/E - EPS (ttm) - Insider Own 49.29% Shs Outstand 17.58M Perf Week -10.10%
Market Cap 274.48M Forward P/E - EPS next Y - Insider Trans 114.85% Shs Float 12.32M Perf Month -9.96%
Income - PEG - EPS next Q -0.83 Inst Own 41.37% Short Float 6.83% Perf Quarter -4.24%
Sales - P/S - EPS this Y - Inst Trans - Short Ratio 5.35 Perf Half Y -
Book/sh -8.21 P/B - EPS next Y - ROA - Short Interest 0.84M Perf Year -
Cash/sh 1.92 P/C 5.90 EPS next 5Y - ROE - 52W Range 9.71 - 17.31 Perf YTD -5.83%
Dividend Est. - P/FCF - EPS past 5Y -63.82% ROI - 52W High -34.72% Beta -
Dividend TTM - Quick Ratio 4.59 Sales past 5Y 181.38% Gross Margin - 52W Low 16.37% ATR (14) 1.55
Dividend Ex-Date - Current Ratio 4.59 EPS Y/Y TTM - Oper. Margin - RSI (14) 41.36 Volatility 17.79% 12.72%
Employees 77 Debt/Eq 0.62 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 21.25
Option/Short No / Yes LT Debt/Eq 0.47 EPS Q/Q -18.29% Payout - Rel Volume 0.53 Prev Close 10.48
Sales Surprise -100.00% EPS Surprise -1579.39% Sales Q/Q -100.00% Earnings Aug 29 AMC Avg Volume 157.14K Price 11.30
SMA20 -19.54% SMA50 -8.41% SMA200 -6.99% Trades
Volume 85,073 Change 7.82%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Initiated Wedbush
Outperform
$18
Aug-13-24 Initiated TD Cowen
Buy
Aug-13-24 Initiated Needham
Buy
$23
Aug-13-24 Initiated Jefferies
Buy
$21
Aug-13-24 Initiated Cantor Fitzgerald
Overweight
$23
Oct-22-24 04:05PM
Sep-10-24 04:05PM
Aug-29-24 04:05PM
Jul-18-24 07:08PM
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
RA CAPITAL MANAGEMENT, L.P. Director Jul 22 '24 Buy 12.00 8,333,333 99,999,996 8,693,579 Jul 24 04:27 PM 5AM Partners VI, LLC 10% Owner Jul 22 '24 Buy 12.00 833,333 9,999,996 1,182,054 Jul 24 04:15 PM venBio Global Strategic Fund I 10% Owner Jul 22 '24 Buy 12.00 416,666 4,999,992 1,936,637 Jul 22 08:26 PM GC Corp. 10% Owner Jul 22 '24 Buy 12.00 1,666,666 19,999,992 3,306,900 Jul 22 08:25 PM GC Corp. 10% Owner Jul 22 '24 Buy 12.00 416,666 4,999,992 1,260,512 Jul 22 08:25 PM Huh Yong-Jun Director Jul 22 '24 Buy 12.00 2,083,332 24,999,984 3,306,900 Jul 22 08:22 PM
Index RUT P/E - EPS (ttm) -1.93 Insider Own 38.61% Shs Outstand 41.29M Perf Week 4.17%
Market Cap 1.37B Forward P/E - EPS next Y -2.47 Insider Trans -11.76% Shs Float 29.00M Perf Month 22.95%
Income -82.83M PEG - EPS next Q -0.51 Inst Own 70.11% Short Float 21.05% Perf Quarter 20.70%
Sales 0.00M P/S - EPS this Y 3.31% Inst Trans 24.26% Short Ratio 25.54 Perf Half Y 66.84%
Book/sh 6.46 P/B 4.48 EPS next Y -27.27% ROA -26.91% Short Interest 6.10M Perf Year 129.09%
Cash/sh 6.61 P/C 4.38 EPS next 5Y - ROE -28.37% 52W Range 9.80 - 30.03 Perf YTD 109.39%
Dividend Est. - P/FCF - EPS past 5Y 5.16% ROI -27.16% 52W High -3.50% Beta 1.09
Dividend TTM - Quick Ratio 14.39 Sales past 5Y 0.00% Gross Margin - 52W Low 195.71% ATR (14) 1.20
Dividend Ex-Date - Current Ratio 14.39 EPS Y/Y TTM -164.59% Oper. Margin 0.00% RSI (14) 70.56 Volatility 3.72% 4.73%
Employees 46 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.17 Target Price 35.60
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -1.67% Payout - Rel Volume 0.83 Prev Close 28.87
Sales Surprise - EPS Surprise 25.45% Sales Q/Q - Earnings Aug 13 AMC Avg Volume 239.02K Price 28.98
SMA20 7.44% SMA50 18.92% SMA200 40.39% Trades
Volume 196,880 Change 0.38%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-09-24 Initiated H.C. Wainwright
Buy
$37
Jun-11-24 Initiated Robert W. Baird
Outperform
$32
Apr-09-24 Initiated Mizuho
Buy
$34
Mar-29-23 Initiated Jefferies
Buy
$27
Oct-18-24 04:38PM
Oct-04-24 09:00AM
Sep-30-24 04:52AM
(Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM
Sep-26-24 08:50AM
04:05PM
Loading…
Sep-18-24 04:05PM
Sep-09-24 02:05PM
Sep-04-24 09:55AM
Aug-16-24 09:55AM
Aug-13-24 04:05PM
May-29-24 04:05PM
(GlobeNewswire) -8.14%
+5.67%
May-20-24 05:06PM
May-14-24 10:54PM
05:01PM
04:05PM
03:03PM
Loading…
Apr-19-24 03:03PM
Apr-11-24 03:44PM
07:55AM
Apr-09-24 04:05PM
Mar-28-24 04:05PM
(GlobeNewswire) -5.58%
+7.45%
Mar-23-24 01:51AM
Mar-19-24 08:30AM
Mar-14-24 09:53PM
04:05PM
Feb-27-24 04:05PM
Jan-03-24 09:01AM
Nov-09-23 04:05PM
Aug-17-23 06:40AM
Aug-10-23 04:05PM
May-31-23 04:55PM
04:05PM
Loading…
May-11-23 04:05PM
Mar-24-23 06:30AM
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Patel Anish CHIEF OPERATING OFFICER Oct 18 '24 Sale 30.00 716 21,483 343,311 Oct 22 04:23 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Oct 18 '24 Sale 30.00 847 25,413 1,015,188 Oct 22 04:22 PM Kintz Samuel PRESIDENT AND CEO Oct 18 '24 Sale 30.00 924 27,723 1,002,892 Oct 22 04:21 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 18 '24 Option Exercise 2.48 814 2,019 814 Oct 22 04:19 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 18 '24 Sale 30.00 814 24,422 0 Oct 22 04:19 PM Heyman Richard A. Director Oct 18 '24 Sale 30.00 817 24,512 123,673 Oct 22 04:18 PM Heyman Richard A. Director Oct 18 '24 Sale 30.00 753 22,592 27,165 Oct 22 04:18 PM Collins Helen Louise CHIEF MEDICAL OFFICER Oct 18 '24 Option Exercise 2.48 816 2,024 816 Oct 22 04:17 PM Collins Helen Louise CHIEF MEDICAL OFFICER Oct 18 '24 Sale 30.00 816 24,482 0 Oct 22 04:17 PM Patel Anish Officer Oct 18 '24 Proposed Sale 28.02 50,000 1,401,000 Oct 18 06:42 PM Lyssikatos Joseph P Officer Oct 18 '24 Proposed Sale 28.02 65,000 1,821,300 Oct 18 05:42 PM Heyman Richard A. Director Oct 18 '24 Proposed Sale 28.02 1,566 43,879 Oct 18 05:27 PM Kintz Samuel Officer Oct 18 '24 Proposed Sale 28.02 91,123 2,553,266 Oct 18 05:17 PM Heyman Richard A. Director Oct 18 '24 Proposed Sale 28.02 12,165 340,863 Oct 18 05:10 PM Hohl Benjamin Officer Oct 18 '24 Proposed Sale 28.02 13,000 364,260 Oct 18 05:00 PM Collins Helen Louise Officer Oct 18 '24 Proposed Sale 28.02 25,000 700,500 Oct 18 04:57 PM Heyman Richard A. Director Oct 15 '24 Sale 27.67 1,270 35,143 124,490 Oct 17 05:06 PM Heyman Richard A. Director Oct 15 '24 Proposed Sale 27.75 1,270 35,242 Oct 15 04:38 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Oct 09 '24 Sale 28.16 37,878 1,066,561 1,016,035 Oct 10 08:39 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Oct 08 '24 Sale 27.97 13,267 371,024 1,053,913 Oct 10 08:39 PM Kintz Samuel PRESIDENT AND CEO Oct 09 '24 Sale 28.15 16,710 470,405 1,003,816 Oct 10 08:38 PM Kintz Samuel PRESIDENT AND CEO Oct 08 '24 Sale 27.96 13,267 370,929 1,020,526 Oct 10 08:38 PM Ballal Rahul D. Director Oct 08 '24 Option Exercise 14.10 10,420 146,925 32,761 Oct 10 08:36 PM Ballal Rahul D. Director Oct 08 '24 Sale 28.17 10,420 293,557 22,341 Oct 10 08:36 PM Lyssikatos Joseph P Officer Oct 09 '24 Proposed Sale 28.01 12,000 336,120 Oct 09 04:27 PM Kintz Samuel Officer Oct 09 '24 Proposed Sale 28.01 12,000 336,120 Oct 09 04:16 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Oct 04 '24 Sale 27.51 7,522 206,937 1,069,887 Oct 08 06:58 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Oct 07 '24 Sale 27.61 2,707 74,727 1,067,180 Oct 08 06:58 PM Kintz Samuel PRESIDENT AND CEO Oct 04 '24 Sale 27.51 12,206 335,792 1,036,523 Oct 08 06:57 PM Kintz Samuel PRESIDENT AND CEO Oct 07 '24 Sale 27.50 2,730 75,075 1,033,793 Oct 08 06:57 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 04 '24 Option Exercise 2.48 10,218 25,341 10,218 Oct 08 06:56 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 07 '24 Option Exercise 2.48 1,270 3,150 2,000 Oct 08 06:56 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 04 '24 Sale 27.51 10,218 281,079 0 Oct 08 06:56 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 07 '24 Sale 27.51 1,270 34,935 0 Oct 08 06:56 PM Heyman Richard A. Director Oct 04 '24 Sale 27.51 2,825 77,704 125,760 Oct 08 06:54 PM Ballal Rahul D. Director Oct 08 '24 Proposed Sale 27.45 10,420 286,029 Oct 08 03:59 PM Heyman Richard A. Director Oct 04 '24 Proposed Sale 25.51 2,540 64,795 Oct 04 04:28 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Oct 01 '24 Sale 27.54 527 14,512 1,077,409 Oct 03 06:47 PM Kintz Samuel PRESIDENT AND CEO Oct 01 '24 Sale 27.54 526 14,485 1,048,729 Oct 03 06:45 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 01 '24 Option Exercise 2.48 521 1,292 521 Oct 03 06:44 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Oct 01 '24 Sale 27.54 521 14,347 0 Oct 03 06:44 PM Heyman Richard A. Director Oct 01 '24 Sale 27.54 518 14,264 128,585 Oct 03 06:43 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Sep 27 '24 Option Exercise 2.48 4,250 10,540 4,250 Oct 01 07:53 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Sep 30 '24 Option Exercise 2.48 2,000 4,960 2,000 Oct 01 07:53 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Sep 27 '24 Sale 24.27 4,250 103,161 0 Oct 01 07:53 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Sep 30 '24 Sale 25.33 2,000 50,668 0 Oct 01 07:53 PM Hohl Benjamin Officer Oct 01 '24 Proposed Sale 25.54 12,009 306,710 Oct 01 04:14 PM Hohl Benjamin Officer Sep 30 '24 Proposed Sale 24.13 491 11,848 Sep 30 04:19 PM Heyman Richard A. Director Sep 16 '24 Sale 22.41 1,270 28,458 129,103 Sep 18 04:17 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Aug 29 '24 Sale 22.49 12,000 269,841 1,077,936 Sep 03 05:43 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Aug 27 '24 Option Exercise 2.48 4,250 10,540 4,250 Aug 29 06:36 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Aug 27 '24 Sale 22.54 4,250 95,782 0 Aug 29 06:36 PM Kintz Samuel PRESIDENT AND CEO Aug 26 '24 Sale 22.89 12,000 274,718 1,049,255 Aug 28 07:48 PM Heyman Richard A. Director Aug 15 '24 Sale 23.25 1,270 29,526 130,373 Aug 19 07:49 PM Kintz Samuel Member of immediate family of Aug 19 '24 Proposed Sale 23.71 30,000 711,300 Aug 19 04:32 PM Kintz Samuel Member of immediate family of Aug 19 '24 Proposed Sale 23.71 30,000 711,300 Aug 19 04:32 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Jul 31 '24 Sale 27.56 3,099 85,399 1,089,936 Aug 02 07:26 PM Kintz Samuel PRESIDENT AND CEO Jul 31 '24 Sale 27.56 2,270 62,555 1,061,255 Aug 02 07:25 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 31 '24 Option Exercise 2.48 991 2,458 991 Aug 02 07:23 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 31 '24 Sale 27.53 991 27,281 0 Aug 02 07:23 PM Heyman Richard A. Director Jul 31 '24 Sale 27.51 1,702 46,815 131,643 Aug 02 07:22 PM Heyman Richard A. Director Jul 31 '24 Sale 27.50 649 17,848 27,918 Aug 02 07:22 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Jul 29 '24 Sale 26.70 12,000 320,378 1,093,035 Jul 31 07:33 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 29 '24 Option Exercise 2.48 5,250 13,020 5,250 Jul 31 07:31 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 29 '24 Sale 26.68 5,250 140,052 0 Jul 31 07:31 PM Heyman Richard A. Director Jul 31 '24 Proposed Sale 26.13 649 16,958 Jul 31 04:57 PM Heyman Richard A. Director Jul 31 '24 Proposed Sale 26.13 5,045 131,826 Jul 31 04:31 PM Hohl Benjamin Officer Jul 31 '24 Proposed Sale 26.13 11,000 287,430 Jul 31 04:30 PM Lyssikatos Joseph P Officer Jul 31 '24 Proposed Sale 26.13 65,000 1,698,450 Jul 31 04:23 PM Kintz Samuel Officer Jul 31 '24 Proposed Sale 26.13 47,709 1,246,636 Jul 31 04:22 PM Kintz Samuel PRESIDENT AND CEO Jul 25 '24 Sale 24.92 12,000 299,073 1,063,525 Jul 29 05:39 PM Hohl Benjamin Officer Jul 29 '24 Proposed Sale 27.31 5,250 143,378 Jul 29 04:15 PM Lyssikatos Joseph P Officer Jul 29 '24 Proposed Sale 27.31 12,000 327,720 Jul 29 04:06 PM Heyman Richard A. Director Jul 15 '24 Sale 24.80 1,270 31,497 133,345 Jul 17 07:25 PM Patel Anish CHIEF OPERATING OFFICER Jul 15 '24 Sale 25.05 30,978 776,039 345,574 Jul 16 05:37 PM Patel Anish CHIEF OPERATING OFFICER Jul 12 '24 Sale 25.07 17,475 438,095 376,552 Jul 16 05:37 PM Patel Anish CHIEF OPERATING OFFICER Jul 16 '24 Sale 25.01 1,547 38,692 344,027 Jul 16 05:37 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 12 '24 Option Exercise 2.48 3,000 7,440 3,000 Jul 16 05:34 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jul 12 '24 Sale 25.07 3,000 75,195 0 Jul 16 05:34 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER Jul 01 '24 Sale 22.89 12,000 274,736 1,105,035 Jul 03 04:31 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jun 27 '24 Option Exercise 2.48 4,250 10,540 4,250 Jul 01 08:03 PM Hohl Benjamin CHIEF FINANCIAL OFFICER Jun 27 '24 Sale 22.57 4,250 95,922 0 Jul 01 08:03 PM Kintz Samuel PRESIDENT AND CEO Jun 25 '24 Sale 21.66 12,000 259,902 1,075,525 Jun 27 04:35 PM Heyman Richard A. Director Jun 17 '24 Sale 21.48 1,270 27,278 134,615 Jun 20 07:20 PM Patel Anish CHIEF OPERATING OFFICER Jun 06 '24 Option Exercise 2.48 1,133 2,810 1,133 Jun 10 06:46 PM Patel Anish CHIEF OPERATING OFFICER Jun 06 '24 Sale 20.06 1,133 22,722 0 Jun 10 06:46 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER May 29 '24 Option Exercise 1.12 12,000 13,440 12,000 May 31 04:05 PM Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER May 29 '24 Sale 21.73 12,000 260,800 0 May 31 04:05 PM Kintz Samuel PRESIDENT AND CEO May 28 '24 Option Exercise 1.12 12,000 13,440 12,000 May 30 05:56 PM Kintz Samuel PRESIDENT AND CEO May 28 '24 Sale 23.18 12,000 278,210 0 May 30 05:56 PM Hohl Benjamin CHIEF FINANCIAL OFFICER May 28 '24 Option Exercise 2.48 4,250 10,540 4,250 May 30 05:54 PM Hohl Benjamin CHIEF FINANCIAL OFFICER May 28 '24 Sale 23.18 4,250 98,530 0 May 30 05:54 PM Heyman Richard A. Director May 16 '24 Sale 23.74 1,270 30,150 135,885 May 20 07:46 PM Gupta Rishi Director May 16 '24 Sale 22.14 1,033,300 22,877,262 254,814 May 20 05:03 PM ORBIMED ADVISORS LLC Director May 16 '24 Sale 22.14 1,033,300 22,877,262 254,814 May 20 05:00 PM Patel Anish CHIEF OPERATING OFFICER May 14 '24 Option Exercise 2.48 1,107 2,745 1,107 May 16 07:29 PM Patel Anish CHIEF OPERATING OFFICER May 14 '24 Sale 25.00 1,107 27,675 0 May 16 07:29 PM Patel Anish CHIEF OPERATING OFFICER May 09 '24 Option Exercise 2.48 260 645 260 May 13 07:35 PM Patel Anish CHIEF OPERATING OFFICER May 09 '24 Sale 25.06 260 6,515 0 May 13 07:35 PM Patel Anish CHIEF OPERATING OFFICER May 06 '24 Option Exercise 2.48 4,875 12,090 4,875 May 08 08:40 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
